THE NOVEL TYPE II CD20 ANTIBODY GA101 MEDIATES SUPERIOR B CELL DEPLETION IN WHOLE BLOOD FROM HEALTHY VOLUNTEERS AND B-CLL PATIENTS

被引：0
|
作者：
Herter, S. [1 ]
Del Giudice, I. [2 ]
Schmidt, C. [1 ]
Fauti, T. [1 ]
Klein, C. [3 ]
Umana, P. [1 ]
Dyer, M. J. S. [4 ]
Foa, R. [2 ]
Grau, R. [1 ]
机构：
[1] Glycart Biotechnol AG, Schlieren, Switzerland
[2] Univ Roma La Sapienza, Rome, Italy
[3] Roche Diagnost GmbH, Penzberg, Germany
[4] Univ Leicester, Leicester, Leics, England
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0910
引用
收藏
页码：366 / 366
页数：1
相关论文
共 50 条
  • [41] Randomized Phase II Trial Comparing GA101 (Obinutuzumab) with Rituximab in Patients with Relapsed CD20+Indolent B-Cell Non-Hodgkin Lymphoma: Preliminary Analysis of the GAUSS Study
    Sehn, Laurie H.
    Goy, Andre
    Offner, Fritz C.
    Martinelli, Giovanni
    Friedberg, Jonathan
    Lasserre, Susan F.
    Fine, Gregg
    Press, Oliver W.
    BLOOD, 2011, 118 (21) : 124 - 124
  • [42] RANDOMIZED PHASE II TRIAL COMPARING OBINUTUZUMAB (GA101) WITH RITUXIMAB IN PATIENTS WITH RELAPSED CD20+INDOLENT B-CELL NON-HODGKIN LYMPHOMA: PRELIMINARY ANALYSIS OF THE GAUSS STUDY
    Goy, A.
    Offner, F.
    Martinelli, G.
    Caballero, D.
    Gadeberg, O.
    Gaidano, G.
    Press, O.
    Fine, G.
    Chai, A.
    Sahin, D.
    Sehn, L.
    HAEMATOLOGICA, 2012, 97 : 322 - 323
  • [43] Quantitative Whole Genome Analysis of Sequential Samples From Patients with B-CLL Identifies Novel Recurrent Copy Number Alterations Involving Critical B-Cell Transcription Factors
    Timbs, Adele
    Knight, Sam
    SadighiAkha, Elham
    Burns, Adam
    Dreau, Helene
    Hewitt, Anne-Marie
    Hatton, Chris
    Yau, Chris
    Holmes, Chris
    Taylor, Jenny
    Schuh, Anna
    BLOOD, 2010, 116 (21) : 1478 - 1478
  • [44] Pharmacodynamics of B-Cell Depletion and Pharmacokinetics of the Novel Anti-CD20 Monoclonal Antibody Ublituximab in Patients With Relapsing Multiple Sclerosis
    Fox, E.
    Steinman, L.
    Hartung, H.
    Alvarez, E.
    Qian, P.
    Wray, S.
    Robertson, D.
    Huang, D.
    Selmaj, K.
    Wynn, D.
    Weiss, M. S.
    Bosco, J. A.
    Power, S. A.
    Mok, K. A.
    Lee, L.
    Cree, B. A.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 68 - 68
  • [45] COMBINATION OF THE GLYCOENGINEERED TYPE II CD20 ANTIBODY OBINUTUZUMAB WITH THE NOVEL BCL-2 SELECTIVE INHIBITOR VENETOCLAX INDUCES ROBUST CELL DEATH IN NHL MODELS AND CLL PATIENT SAMPLES
    Sampath, D.
    Herter, S.
    Ingalla, E.
    Herting, F.
    Friess, T.
    Bacac, M.
    Umana, P.
    Fairbrother, W.
    Ysebaert, L.
    Anne-Quillet, M.
    Klein, C.
    HAEMATOLOGICA, 2016, 101 : 568 - 568
  • [46] Mosunetuzumab, a Novel CD20/CD3 Bispecific Antibody, in Combination with CHOP Confers High Response Rates in Patients with Diffuse Large B-Cell Lymphoma
    Phillips, Tycel J.
    Olszewski, Adam J.
    Munoz, Javier
    Kim, Tae Min
    Yoon, Dok Hyun
    Greil, Richard
    Westin, Jason
    Jaeger, Ulrich
    Canales, Miguel
    Chen, Cindy
    Althaus, Betsy
    O'Hear, Carol
    Negricea, Raluca
    Xie, Yuying
    McCord, Ronald
    Purev, Enkhtsetseg
    Vallurupalli, Anusha
    BLOOD, 2020, 136
  • [47] Promising Efficacy with the New Anti-CD20 Antibody GA101 In Heavily Pre-Treated NHL Patients - First Results From a Phase II Study In Patients with Relapsed/Refractory DLBCL and MCL
    Cartron, Guillaume
    Thieblemont, Catherine
    Solal-Celigny, Philippe
    Morschhhauser, Franck
    Haioun, Corinne
    Bouabdallah, Reda
    Lamy, Thierry
    Milpied, Noel
    Le Gouill, Steven
    Feugier, Pierre
    Birkett, Joe
    Wenger, Michael K.
    Asikanius, Elina
    Salles, Gilles
    BLOOD, 2010, 116 (21) : 1185 - 1186
  • [48] PROMISING EFFICACY WITH THE NEW ANTI-CD20 ANTIBODY GA101 IN HEAVILY PRE-TREATED PATIENTS - FIRST RESULTS FROM A PHASE II STUDY IN PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NHL (INHL)
    Salles, A.
    Morschhauser, F.
    Thieblemont, C.
    Solal-Celigny, P.
    Lamy, T.
    Tilly, H.
    Feugier, P.
    Le Gouill, S.
    Gyan, E.
    Bouabdallah, R.
    Wenger, M.
    Birkett, J.
    Cartron, G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 229 - 230
  • [49] Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)
    Lundin, J
    Kimby, E
    Björkholm, M
    Broliden, PA
    Celsing, F
    Hjalmar, V
    Möllgård, L
    Rebello, P
    Hale, G
    Waldmann, H
    Mellstedt, H
    Österborg, A
    BLOOD, 2002, 100 (03) : 768 - 773
  • [50] Bi20 (FBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels
    Stanglmaier, Michael
    Faltin, Margot
    Ruf, Peter
    Bodenhausen, Annette
    Schroeder, Petra
    Lindhofer, Horst
    INTERNATIONAL JOURNAL OF CANCER, 2008, 123 (05) : 1181 - 1189
12345